Novo Nordisk's Paediatric Data Offers Rare Cheer as Investors Brace for London Strategy Session

Novo's semaglutide cut child obesity to 40.4% vs 0% placebo, but shares lag amid ziltivekimab trial halts and pipeline concerns.

The arithmetic of obesity in childhood is unforgiving, and Novo Nordisk's latest clinical readout offers a striking contrast: 40.4 percent of children aged six to under 12 treated with once-weekly semaglutide in the Phase 3 STEP Young study no longer met the threshold for obesity after 68 weeks, against zero percent in the placebo arm. More than 85 percent of participants entered the trial with severe Class 2 or 3 obesity, and investigators flagged no new safety concerns relating to growth or pubertal development. Full findings are slated for presentation at the ObesityWeek conference in Washington this November.

The result extends the Danish drugmaker's dominance in metabolic medicine to younger patients than ever before, reinforcing semaglutide's efficacy across adults, adolescents and now school-age children. Yet the shares have barely stirred. The stock changes hands at roughly €39, down about 29 percent from its 52-week high of €54.86 touched in January, and sits below its 50-day moving average of €41.54 — technical evidence that the near-term trend remains pointed south.

A Single Day of Contradictions

The paediatric milestone landed on 7 September, the same day Novo Nordisk was forced to terminate two further studies of its experimental cardiovascular candidate ziltivekimab. HERMES and ATHENA were halted after a data monitoring committee concluded they would likely produce no better outcome than ZEUS, the trial that failed in July. The company's ARTEMIS Phase 3 programme in heart failure continues as planned, with data expected in the first half of 2027, but the pipeline beyond semaglutid has narrowed appreciably.

That contraction is the central question hanging over the capital markets day scheduled for 21 September in London, where management is expected to outline its medium-term strategy and address how it intends to fill the ziltivekimab gap. The timing has drawn criticism from observers who note the meeting coincides with a stretch of negative pipeline headlines — the paediatric data providing at least some counterweight.

Can One Franchise Carry the Growth Story?

With ziltivekimab's heart failure ambitions diminished, the company's growth base now rests almost entirely on the diabetes and obesity franchise built around semaglutide, marketed as Ozempic and Wegovy. The pivotal question for investors: can the Wegovy family — including the oral tablet formulation, for which Chinese regulators have accepted a filing for review and which has already secured approvals in the US, UK, EU, UAE and Bahrain — sustain the growth trajectory the market has priced in?

Early signals are mixed. The tablet's German launch last Friday has been subdued, and the shares have slipped around 2.4 percent since, a modest but telling indication of how critically the market scrutinises every new avenue of growth.

Bullish observers point to China as a potential catalyst of enormous scale for oral obesity therapies, a segment where Novo Nordisk already claims first-mover status. The STEP Young data, meanwhile, expands the addressable patient population into younger cohorts and provides additional regulatory evidence for future label expansions. If management delivers a credible response to the ziltivekimab setback at the London meeting, it could act as a confidence signal and lift the shares from their depressed levels.

Divergent Views on Valuation

The valuation debate remains sharply contested. Barclays analysts trimmed their price target to 300 Danish kroner from 310, maintaining an "equal-weight" rating. Deutsche Bank has been more aggressive, downgrading the stock to sell on 27 August and again on 7 September, cutting its target to 265 Danish kroner on the back of softening 2027 growth prospects, the pipeline setbacks and what it describes as substantial patent cliff risk later in the decade.

Other observers employing discounted cash flow models arrive at considerably higher fair values, while some cash-flow-based approaches flag the equity as overvalued. The wide dispersion underscores just how differently the market weighs near-term pipeline disappointments against the long-term substance of the obesity franchise.

Buyback Programme Continues Unabated

Despite the share price volatility, Novo Nordisk has pressed on with its repurchase programme. Since the start of February, the company has acquired roughly 32 million B-shares at an average price of 281.63 Danish kroner, for a total volume of around 9 billion kroner — part of a broader 15 billion kroner buyback authorised by the board. The purchases signal management's conviction in the company's long-term value, even as the equity trades well below its January peak.

In a separate corporate development, Ulla Grove Krogsgaard Thomsen is stepping down as chief executive of Novo Nordisk Pharmatech, the group's subsidiary. She leaves behind a business that has nearly doubled under her leadership, though the unit anticipates a revenue decline in the current year.

Competitive Pressures Mount

The competitive landscape in the GLP-1 arena continues to intensify. Sandoz, the generics and biosimilars specialist carved out of Novartis, has raised its medium-term guidance and now targets around 100 biosimilar products by 2040 — an ambition aided by the eventual expiry of semaglutide's patent protection on Ozempic and Wegovy.

The near-term catalysts are now clearly defined: the capital markets day on 21 September, followed by nine-month results on 4 November. Both will test whether Novo Nordisk can persuade investors that a single, albeit broad, pillar named semaglutid can support the growth narrative — and whether the paediatric triumph can eventually translate into the share price response it has so far failed to generate.